IPILIMUMAB

Ipilimumab is an active pharmaceutical component indicated for treatment of advanced melanoma, a type of skin cancer that has spread to other body parts. In adults, it is also used to treat cancer of the lungs, liver, and kidneys. It is indicated for treatment of colorectal cancer in adults and children aged 12 years and older. Cancer is characterised by uncontrolled and abnormal multiplication of cells. Like many cancer treatments, ipilimumab can cause side effects including fatigue, diarrhoea, and skin rash; these side effects are typically manageable with appropriate medical care. Ipilimumab received initial approval from the US FDA (Food and Drug Administration) on 25 March 2011 for treatment of unresectable or metastatic melanoma, a spreading type of skin cancer. Since then, it has been approved for additional indications, including treatment of advanced renal cell carcinoma. The primary benefit of ipilimumab is that it can help improve survival in patients with advanced melanoma.

Ipilimumab is a medication used to treat advanced melanoma, a type of skin cancer that has spread to other parts of the body. It is also combined with other immunotherapeutic agents or chemotherapy for treating other types of cancer, such as advanced lung and kidney cancer. It is also used in the treatment of liver and colorectal cancer.

A healthcare professional typically administers Ipilimumab through an intravenous (IV) infusion. The medication is prepared as a solution and given for about 90 minutes. The dose will depend on factors such as the patient's weight and overall health and the specific cancer being treated. Treatment is typically given in cycles, each consisting of several infusions over weeks or months. If you miss a dose of this medication, it is important to contact your healthcare provider as soon as possible to discuss your options. The timing and frequency of doses can be critical in achieving the maximum benefit from the medication.

Some of the most common side effects of ipilimumab include fatigue, diarrhea, itching, and rash. These side effects are generally mild to moderate and can usually be managed with supportive care. However, it can also cause more serious side effects, known as immune-related adverse events, which result from the activation of the immune system. Examples of immune-related adverse events associated with this include colitis (inflammation of the colon), hepatitis (inflammation of the liver), dermatitis (skin reactions), and endocrinopathies (diabetes, hypothyroidism).

Ipilimumab can cause adverse reactions, be severe or even life-threatening, and affect any organ in the body. Examples of immune-mediated adverse reactions reported with this medication include colitis, hepatitis, dermatitis, neuropathy, and endocrinopathy. Severe or life-threatening skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, are also reported with this medication. It can also cause severe or life-threatening gastrointestinal reactions, such as colitis or diarrhea, and affect the function of the immune system, which can increase the risk of infections. Infusion reactions can occur during or shortly after the infusion of this medication. So it is important to monitor for signs and symptoms throughout treatment with this medication.

Patients with a history of allergic reactions to ipilimumab or its components should not take this medication. It can cause fetal harm during pregnancy, and it is not recommended for use in pregnancy or breastfeeding. Patients with weakened immune systems or a history of immune-related disorders may be at increased risk and should discuss their condition with their healthcare provider before starting treatment. Patients require monitoring during the infusion and for at least 30 minutes after the infusion is complete due to the risk of an infusion reaction.

Ipilimumab is a potent immunotherapy with the potential for serious adverse effects. Adherence to your doctor's dosing instructions and prompt reporting of any side effects or health changes is essential. Contact your healthcare provider immediately if you experience an infusion reaction. Women of childbearing potential should use effective contraception during treatment and for at least three months following the final dose. Inform your physician if you follow a sodium-restricted diet, as this medication contains sodium. Patients receiving cancer treatment are advised to consume a diet comprising fruits, vegetables, whole grains, and lean proteins whilst limiting processed and high-fat foods. Adequate hydration through sufficient water intake is also important.

Bristol-Myers Squibb Company, US Food and Drug Administration, [Revised on May 2020] [ Accessed on 15 April 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s110lbl.pdf Bristol-Myers Squibb Pharma EEIG, Electronic medicines compendium (emc), [Revised on Jan 2021] [ Accessed on 15th April], https://www.medicines.org.uk/emc/files/pil.4683.pdf Matthew D Hellmann et al; Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer; The New England Journal of Medicine; Published on Nov 2019; Accessed on 15th April 2023]; https://pubmed.ncbi.nlm.nih.gov/31562796/